BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma, a biotech firm specializing in mental disorder treatments, has closed a non-brokered private placement, issuing 5.3 million units at $0.10 per unit. This generated $530,000 in gross proceeds. Each unit includes one common share and one warrant, with a warrant exercise price of $0.13, valid for 24 months. CEO Dr. Ahmad Doroudian subscribed for 500,000 units, categorized as a 'related party transaction.' The transaction met exemptions under MI 61-101. BetterLife plans an additional private placement tranche to raise up to $100,000.
BetterLife Pharma, an emerging biotech company, announced successful completion of its animal GLP cardiopulmonary safety study for BETR-001, a non-hallucinogenic derivative of LSD. The study showed no significant safety issues at doses over 100 times the projected starting dose for human trials. Key findings include no effects on ECG, respiratory parameters, body temperature, and activity levels. BETR-001's safety profile contrasts with LSD and psilocybin, known for cardiac toxicity due to 5-HT2B receptor agonism. BetterLife plans to file the BETR-001 IND by the end of 2024. Additionally, the company issued over 1 million common shares and warrants as part of a convertible debenture conversion totaling $103,534.20, with warrants exercisable at $0.10 per share until December 2025.
BetterLife Pharma Inc. announced its intent to conduct a Non-Brokered Private Placement offering of up to $500,000 to advance its lead compound BETR-001, a non-hallucinogenic LSD derivative, for mental disorders. The offering consists of units containing common shares and warrants.
BetterLife Pharma Inc. announces progress in its IND-enabling studies for BETR-001, a non-hallucinogenic LSD derivative for mental disorders. The company has initiated GLP studies for metabolism and genotoxicity. BETR-001 has shown robust activity in animal models without hallucinogenic effects. BetterLife plans to file the IND application with the FDA by the end of 2024.
In March 2024, BetterLife disclosed its intention to conduct private placement offerings of Convertible Debentures to fund the development of BETR-001. The company closed a tranche of $30,000 10% Convertible Debentures with a two-year maturity to further advance BETR-001 development. Each Convertible Debenture is convertible into units of the company, including one common share and one share purchase warrant.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.